Journal
The CMS BALANCE Model, Explained: Negotiated GLP-1 Prices for Medicaid and Part D, the 2026 Application Window, and What Actually Changes for You
Released: Last reviewed:
The short answer
The BALANCE Model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — is a voluntary CMS Innovation Center program that was built to let state Medicaid agencies, and originally Medicare Part D plans, cover GLP-1 medications at federally negotiated prices, announced in December 2025. The Medicaid timeline is the live one: the model opened to state applications May 1, 2026 on a rolling basis — per CMS's own model page, states can join at any point through January 1, 2027, with participating states' coverage live no later than that date. On the Medicare side, CMS's BALANCE page (modified September 29, 2026) includes an FAQ about "the BALANCE Model not launching in Medicare in 2027". The negotiated drug list spans both medications this site covers and the next one: Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen, and orforglipron — the oral GLP-1 approved April 1, 2026. Participating states adopt standardized coverage criteria they may broaden but not tighten, and every beneficiary receiving a GLP-1 under BALANCE gets a manufacturer-funded lifestyle-support program at no cost. The honest core: as of the April 2026 verification, CMS had published no list of participating states, and participation is voluntary — a state under budget pressure can decline even at negotiated prices. BALANCE is the biggest potential upside on the Medicaid map and it guarantees nothing until your state's name appears on a participation list.
What the model actually does
Three mechanisms, per the CMS materials the trackers summarize. Negotiated prices: CMS negotiates with manufacturers so participating states pay standardized, lower rates on the named drug list — attacking the exact math that drove the 2026 cuts, where KFF's data shows Medicaid GLP-1 prescriptions rising from about one million in 2019 to over eight million in 2024 and gross spending from roughly one billion to nearly nine billion dollars. Standardized criteria: participating states adopt CMS's coverage criteria as a floor — they can be broader but not more restrictive — which would end the fifty-flavors problem this site's state pages document, where Michigan requires morbid obesity and bariatric-surgery avoidance while Delaware publishes no extraordinary gates. The lifestyle program: every BALANCE beneficiary on a GLP-1 gets manufacturer-funded lifestyle and nutrition support at no cost — structurally significant because documented lifestyle intervention is the PA component enrollees most often lack, and under BALANCE it comes bundled instead of being a hurdle. States can begin with fee-for-service populations and phase managed care in later.
The timeline, and both halves of it
The Medicaid half: announced December 23, 2025, with manufacturer applications and state notices of intent due January 8, 2026; state enrollment opened May 1, 2026 and — a correction this page logged against its earlier tracker sourcing — runs on a rolling basis through January 1, 2027 per CMS's model page and provider bulletins, not a closed mid-summer window. Participating states' coverage must be live by January 1, 2027. As of this page's August 11 capture no public participating-state list exists, and under rolling enrollment an announcement can land in any month between now and the deadline. On the Medicare side, CMS set an April 30, 2026 target for notifying participating manufacturers and Part D plan sponsors, with the Part D performance period running January 1, 2027 through December 31, 2031 — dates that now have to be read against the FAQ on CMS's model page, modified September 29, 2026, about "the BALANCE Model not launching in Medicare in 2027." The Medicare half runs parallel and is easy to confuse with a different program: the separate Medicare GLP-1 Bridge that began July 1, 2026 — a $50 copay for eligible Part D enrollees on Foundayo, Wegovy or the Zepbound KwikPen, covered on our Medicare page and now extended through December 31, 2027 — is already live, while BALANCE's Medicare side is the subject of CMS's FAQ about "the BALANCE Model not launching in Medicare in 2027". Two programs, two timelines; a Medicare enrollee reading about BALANCE should know the bridge may already apply to them today.
What it means by situation, honestly
If your state already covers — the eleven-to-thirteen on the Medicaid hub's August count, before Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss effective October 1, 2026 (Point32Health/Tufts Health RITogether provider notice); coverage continues for type 2 diabetes and other FDA-approved indications — BALANCE participation would mean lower state costs (stabilizing the benefit against the budget pressure that cut California and Pennsylvania), possibly broader criteria than your state's current test, and the bundled lifestyle program. If your state cut coverage in 2026, BALANCE is the realistic re-entry mechanism: the negotiated price directly answers the fiscal rationale every elimination bulletin cited, and whether California, Pennsylvania, or Massachusetts rejoin under it is the single biggest question on the change ledger's watch-list. If your state never covered, BALANCE lowers the barrier to entry but cannot force the door — participation stays voluntary, and states that declined at full price may decline at negotiated price if projected volume still breaks the budget; roughly forty percent of adult Medicaid enrollees have obesity, which is exactly why the volume math frightens state treasurers even at better unit prices. And if you are shopping cash-pay while the policy resolves: the pricing database and the price-change ledger are the market's current answer, verification homework included.
What we're watching
Four items, each of which updates this page when it resolves: the participating-state list, whenever CMS publishes it; whether any 2026-elimination state applies; the standardized criteria's actual thresholds, which decide whether BALANCE coverage is broad in practice or Michigan-strict by default; and orforglipron's placement, since a negotiated oral option changes the adherence and cash-comparison math this site's dose and pricing pages run. Every resolution lands here and on the change ledger, dated and sourced.
Questions people ask
What is the CMS BALANCE Model in one paragraph?
A voluntary CMS Innovation Center program, announced December 2025, that was built to let state Medicaid agencies, and originally Medicare Part D plans, cover GLP-1s at federally negotiated prices — Mounjaro, Ozempic, Rybelsus, Wegovy, Zepbound KwikPen, and oral orforglipron — with standardized coverage criteria and a manufacturer-funded lifestyle program for every beneficiary. Medicaid enrollment opened May 1, 2026 and runs on a rolling basis through January 1, 2027, by which date participating states' coverage must be live. On the Medicare side, CMS's BALANCE page (modified September 29, 2026) includes an FAQ about "the BALANCE Model not launching in Medicare in 2027".
Which states are participating in BALANCE?
Unknown as of our August 11 capture — CMS has published no participating-state list, and enrollment is rolling: per CMS's model page, states can join at any point from May 2026 through January 1, 2027, so an announcement can land in any month. An earlier version of this answer described a closed July 31 application window sourced from a tracker; CMS's own materials supersede it, and the correction is logged.
Is BALANCE the same as the Medicare GLP-1 coverage that started in July 2026?
No — two different programs. The Medicare GLP-1 Bridge, live since July 1, 2026 and extended through December 31, 2027, gives eligible Part D enrollees a $50 copay for Foundayo, Wegovy or the Zepbound KwikPen; BALANCE is a separate model, and CMS's BALANCE page (modified September 29, 2026) includes an FAQ about "the BALANCE Model not launching in Medicare in 2027". Our Medicare page covers the bridge in detail.
Will BALANCE make my state cover GLP-1s?
Only if your state chose to apply — participation is voluntary and no state is required to join. The negotiated pricing answers the fiscal rationale behind the 2026 cuts, which makes BALANCE the realistic re-entry path for states like California and Pennsylvania, but a state can decline even at lower prices if projected volume still breaks its budget.
Does BALANCE cover compounded GLP-1s?
No — the negotiated list is FDA-approved products only. Compounded semaglutide and tirzepatide remain cash-pay outside any Medicaid or Medicare benefit, priced on our database with the standing verification homework.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.